Neurocrine Biosciences Inc vs Palantir Technologies Inc — how do they compare? Neurocrine Biosciences Inc trades at $140.75 (market cap $14.36B), while Palantir Technologies Inc trades at $202.47 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 33.3× Neurocrine Biosciences Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Palantir Technologies Inc for 78 Days on average.
| NBIX | PLTR | |
|---|---|---|
Market Cap | $14.36B | $477.68B |
Volume | 1,237,180 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $185.50 | $207.18 |
52-Week Low | $123.10 | $107.27 |
Typical Hold Time | 23 Days | 78 Days |
Enterprise Value | $14.37B | $468.48B |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Palantir (PLTR) trades at $194.04, up 1.02% today, near its recent high and above the consensus price target of $191.69. The stock shows a bullish technical trend with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company reported robust revenue of $4.48 billion in 2025, with net income surging to $1.63 billion and a net margin of 36.3%, while recent quarters have consistently beaten EPS expectations.
Outlook remains positive driven by AI platform growth and expanding commercial customer base, but high valuation ratios (P/E of 169.9, P/S of 83.02) pose risks. Investor sentiment is buoyed by analyst buy ratings (53.84%) and partnerships like the recent Armada alliance, though competitive pressures and execution challenges are key watchpoints.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →